Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
The funds raised from the Whitathon run are utilized to treat underprivileged children suffering from Retinoblastoma
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a statistically significant reduction in frequency and severity of vasomotor symptoms
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Subscribe To Our Newsletter & Stay Updated
